Scarica l'app Stockscreener
12.71
0.94%
-0.12
Dopo l'orario di chiusura:
12.71
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ADPT Giù?
Forum
Previsione
Precedente Chiudi:
$12.83
Aprire:
$12.82
Volume 24 ore:
1.59M
Relative Volume:
0.85
Capitalizzazione di mercato:
$2.03B
Reddito:
$276.98M
Utile/perdita netta:
$-59.46M
Rapporto P/E:
-31.88
EPS:
-0.3987
Flusso di cassa netto:
$-48.95M
1 W Prestazione:
-6.13%
1M Prestazione:
-12.16%
6M Prestazione:
-7.56%
1 anno Prestazione:
+40.44%
Intervallo 1D:
$12.50
$13.39
Intervallo di 1 settimana:
$12.50
$13.72
Portata 52W:
$8.50
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Nome
Adaptive Biotechnologies Corp
Settore
Industria
Telefono
206-659-0067
Indirizzo
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs TMO, DHR, IDXX, WAT, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
12.71 | 2.05B | 276.98M | -59.46M | -48.95M | -0.3987 |
TMO
Thermo Fisher Scientific Inc
|
442.00 | 162.90B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
163.86 | 114.60B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
545.79 | 41.71B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
332.19 | 32.32B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.11 | 31.57B | 7.07B | 1.29B | 993.00M | 4.5355 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Iniziato | Guggenheim | Buy |
| 2025-06-18 | Iniziato | Craig Hallum | Buy |
| 2025-03-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-12-21 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Underperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2022-02-16 | Reiterato | BTIG Research | Buy |
| 2022-02-16 | Reiterato | BofA Securities | Buy |
| 2022-02-16 | Reiterato | Goldman | Neutral |
| 2022-02-16 | Reiterato | JP Morgan | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-03-03 | Downgrade | Goldman | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Iniziato | Goldman | Buy |
| 2019-07-23 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | BofA/Merrill | Buy |
| 2019-07-22 | Iniziato | Cowen | Outperform |
| 2019-07-22 | Iniziato | Goldman | Neutral |
| 2019-07-22 | Iniziato | Guggenheim | Buy |
| 2019-07-22 | Iniziato | William Blair | Outperform |
Mostra tutto
Adaptive Biotechnologies Corp Borsa (ADPT) Ultime notizie
Proposed sale of 3,160 RSUs by ADPT (NASDAQ: ADPT) reported - Stock Titan
Viking firms hold 18.8% of Adaptive Biotechnologies (NASDAQ: ADPT) - Stock Titan
ADPT Stock Price, Quote & Chart | ADAPTIVE BIOTECHNOLOGIES (NASDAQ:ADPT) - ChartMill
ADPT SEC FilingsAdaptive Biotechnologies 10-K, 10-Q, 8-K Forms - Stock Titan
ADPT Maintained by Morgan Stanley -- Price Target Lowered to $18 - GuruFocus
Morgan Stanley Cuts Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $18.00 - MarketBeat
Assessing Adaptive Biotechnologies (ADPT) Valuation After Strong MRD Growth And Raised Full Year Guidance - Yahoo Finance
Analysts Expect Breakeven For Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Before Long - Moomoo
How Strong MRD Growth and Upgraded 2026 Guidance Will Impact Adaptive Biotechnologies (ADPT) Investors - simplywall.st
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2026 Earnings Call Transcript - Insider Monkey
Adaptive Biotech Q1 2026 slides: MRD revenue surges 53%, guidance raised - Investing.com Australia
Adaptive Biotechnologies (NASDAQ:ADPT) Given Buy Rating at Guggenheim - MarketBeat
Adaptive Biotechnologies Corporation 10-Q Report 2026: Financial Statements, Risk Factors, and Forward-Looking Statements 173031 - Minichart
Adaptive Biotech Q1 2026 slides: MRD revenue surges 53%, guidance raised By Investing.com - Investing.com South Africa
Earnings call transcript: Adaptive Biotechnologies Q1 2026 revenue beats forecast By Investing.com - Investing.com South Africa
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: Adaptive Biotechnologies Q1 2026 revenue beats forecast - Investing.com
Transcript: Adaptive Biotechnologies Q1 2026 Earnings Conference Call - Benzinga
Adaptive Biotechnologies: Q1 Earnings Snapshot - marketscreener.com
Adaptive Biotechnologies Corp reports results for the quarter ended March 31Earnings Summary - TradingView
[10-Q] Adaptive Biotechnologies Corp Quarterly Earnings Report - Stock Titan
Q1 2026 Adaptive Biotechnologies Corp Earnings Call Transcript - GuruFocus
MSN Money - MSN
Adaptive Biotechnologies (NASDAQ: ADPT) lifts 2026 MRD outlook after 35% Q1 revenue growth - Stock Titan
Adaptive lifts 2026 MRD outlook after $70.9M quarter, 41% test gain - Stock Titan
Adaptive Biotechnologies earnings on deck after 55% revenue surge By Investing.com - Investing.com South Africa
Adaptive Biotechnologies earnings on deck after 55% revenue surge - Investing.com
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors. - Yahoo Finance
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors. - The Motley Fool
Adaptive Biotechnologies’ Rubinstein sells $1.49m in shares - Investing.com
How The Investment Story For Adaptive Biotechnologies (ADPT) Is Shifting With New Street Assumptions - Yahoo Finance
Adaptive Biotechnologies COO Julie Rubinstein sells $270k in stock By Investing.com - Investing.com UK
Adaptive Biotechnologies Corp (HAM:1HM) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Adaptive Biotechnologies Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Valuation: Significantly Overvalued - GuruFocus
Adaptive Biotechnologies Corp Stock Intrinsic Values | HAM:1HM - GuruFocus
Adaptive Biotechnologies Corp Stock Historical Valuations | HAM:1HM - GuruFocus
Adaptive Biotechnologies Corp Stock Operating Data - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Adaptive Biotechnologies Corp Stock Baskets | HAM:1HM - GuruFocus
Adaptive Biotechnologies Corp Azioni (ADPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.73%
0.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):